TN2013000419A1 - Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors - Google Patents

Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors

Info

Publication number: TN2013000419A1
Authority: TN; Tunisia
Prior art keywords: diseases; kinase; disease; pyrazolo; kinase inhibitors
Prior art date: 2011-04-21

Application number

TNP2013000419A

Other languages

English (en)

Inventor

Michael Almstetter

Michael Thormann

Andreas Treml

Nadine Traube

Original Assignee

Origenis Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-04-21

Filing date

2013-10-14

Publication date

2015-03-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46017783&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2013000419(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2013-10-14 Application filed by Origenis Gmbh filed Critical Origenis Gmbh

2015-03-30 Publication of TN2013000419A1 publication Critical patent/TN2013000419A1/fr

Links

APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
229940043355 kinase inhibitor Drugs 0.000 title 1
239000003757 phosphotransferase inhibitor Substances 0.000 title 1
201000010099 disease Diseases 0.000 abstract 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 abstract 2
102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 abstract 2
102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 abstract 2
108010074596 Myosin-Light-Chain Kinase Proteins 0.000 abstract 2
102000000551 Syk Kinase Human genes 0.000 abstract 2
108010016672 Syk Kinase Proteins 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
208000024827 Alzheimer disease Diseases 0.000 abstract 1
208000023275 Autoimmune disease Diseases 0.000 abstract 1
208000020084 Bone disease Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
208000035473 Communicable disease Diseases 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000012902 Nervous system disease Diseases 0.000 abstract 1
208000025966 Neurological disease Diseases 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
102000001253 Protein Kinase Human genes 0.000 abstract 1
230000007815 allergy Effects 0.000 abstract 1
208000006673 asthma Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000030533 eye disease Diseases 0.000 abstract 1
229940088597 hormone Drugs 0.000 abstract 1
239000005556 hormone Substances 0.000 abstract 1
208000027866 inflammatory disease Diseases 0.000 abstract 1
230000002401 inhibitory effect Effects 0.000 abstract 1
208000030159 metabolic disease Diseases 0.000 abstract 1
230000004770 neurodegeneration Effects 0.000 abstract 1
208000015122 neurodegenerative disease Diseases 0.000 abstract 1
230000000926 neurological effect Effects 0.000 abstract 1
108060006633 protein kinase Proteins 0.000 abstract 1
208000017520 skin disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Pulmonology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Oncology (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Hematology (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Pain & Pain Management (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Transplantation (AREA)
Otolaryngology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

TNP2013000419A 2011-04-21 2013-10-14 Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors TN2013000419A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161517582P	2011-04-21	2011-04-21
PCT/EP2012/001737 WO2012143144A1 (fr)	2011-04-21	2012-04-23	Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases

Publications (1)

Publication Number	Publication Date
TN2013000419A1 true TN2013000419A1 (en)	2015-03-30

Family

ID=46017783

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000419A TN2013000419A1 (en)	2011-04-21	2013-10-14	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors

Country Status (27)

Country	Link
US (1)	US9802937B2 (fr)
EP (1)	EP2699579B1 (fr)
JP (1)	JP6222776B2 (fr)
KR (1)	KR101649611B1 (fr)
CN (1)	CN103492389B (fr)
AP (1)	AP2013007253A0 (fr)
AU (1)	AU2012244550C1 (fr)
BR (1)	BR112013026521A2 (fr)
CA (1)	CA2831634C (fr)
CL (1)	CL2013003051A1 (fr)
CO (1)	CO6831982A2 (fr)
CR (1)	CR20130536A (fr)
CU (1)	CU20130143A7 (fr)
EA (1)	EA029040B1 (fr)
EC (1)	ECSP13012982A (fr)
GT (1)	GT201300255A (fr)
HK (1)	HK1192248A1 (fr)
IL (1)	IL228968A (fr)
MA (1)	MA35124B1 (fr)
MX (1)	MX363696B (fr)
PE (1)	PE20140928A1 (fr)
PH (1)	PH12013502185A1 (fr)
SG (1)	SG194549A1 (fr)
TN (1)	TN2013000419A1 (fr)
TW (1)	TWI606049B (fr)
WO (1)	WO2012143144A1 (fr)
ZA (1)	ZA201307839B (fr)

Families Citing this family (59)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
RU2610840C2 (ru) *	2011-03-28	2017-02-16	Ф. Хоффманн-Ля Рош Аг	Тиазолопиримидины
PE20141066A1 (es)	2011-04-21	2014-09-05	Gilead Sciences Inc	Compuestos de benzotiazol
US9802937B2 (en)	2011-04-21	2017-10-31	Origenis Gmbh	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors
WO2013103738A1 (fr)	2012-01-04	2013-07-11	Gilead Sciences, Inc.	Dérivés d'acide naphtalène acétique contre l'infection par le vih
WO2013103724A1 (fr)	2012-01-04	2013-07-11	Gilead Sciences, Inc.	Dérivés d'acide 2-(tert-butoxy)-2-(7-méthylquinoléin-6-yl)acétique pour traiter le sida
AR090650A1 (es)	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo
US20120323214A1 (en) *	2012-05-16	2012-12-20	Totada R Shantha	Alzheimer's disease treatment with multiple therapeutic agents delivered to the olfactory region through a special delivery catheter and iontophoresis
KR20150027267A (ko)	2012-06-29	2015-03-11	화이자 인코포레이티드	LRRK2 억제제로서의 4-(치환된-아미노)-7H-피롤로[2,3-d]피리미딘
WO2014060112A1 (fr) *	2012-10-19	2014-04-24	Origenis Gmbh	Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases
WO2014134772A1 (fr) *	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
WO2014134776A1 (fr) *	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
WO2014137728A1 (fr)	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Composés inhibant l'activité enzymatique de la kinase à répétition riche en leucine
WO2014134774A1 (fr)	2013-03-04	2014-09-12	Merck Sharp & Dohme Corp.	Composés inhibant l'activité enzymatique de la kinase à séquence répétée riche en leucine
TW201534597A (zh) *	2013-06-20	2015-09-16	Ab Science	作為選擇性蛋白質激酶抑制劑之苯并咪唑衍生物
WO2015026683A1 (fr) *	2013-08-22	2015-02-26	Merck Sharp & Dohme Corp.	Composés inhibant l'activité enzymatique de la kinase à répétitions riches en leucine
WO2015057945A1 (fr)	2013-10-18	2015-04-23	Indiana University Research And Technology Corporation	Effecteurs d'assemblage de virus de l'hépatite b
EP3083618B1 (fr)	2013-12-17	2018-02-21	Pfizer Inc	Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
CA2937431A1 (fr) *	2014-01-29	2015-08-06	Glaxosmithkline Intellectual Property Development Limited	Composes
CA2937430A1 (fr) *	2014-01-29	2015-08-06	Glaxosmithkline Intellectual Property Development Limited	Composes
WO2015162515A1 (fr)	2014-04-25	2015-10-29	Pfizer Inc.	Composés hétéroaromatiques et leur utilisation comme ligands de la dopamine d1
US10004751B2 (en)	2014-07-10	2018-06-26	The J. David Gladstone Institutes	Compositions and methods for treating Dengue virus infection
WO2016130920A2 (fr) *	2015-02-13	2016-08-18	Dana-Farber Cancer Institute, Inc.	Inhibiteurs de lrrk2 et leurs méthodes de production et d'utilisation
CA2982811A1 (fr)	2015-04-17	2016-10-20	Indiana University Research And Technology Corporation	Effecteurs d'assemblage de virus de l'hepatite b
WO2016210331A1 (fr) *	2015-06-26	2016-12-29	Kadmon Corporation, Llc	Traitement de maladies infectieuses à l'aide d'inhibiteurs d'absorption du glucose
CA3028355A1 (fr)	2015-06-26	2016-12-29	Kadmon Corporation, Llc	Inhibiteurs d'absorption du glucose
JP6873980B2 (ja)	2015-09-14	2021-05-19	ファイザー・インク	ＬＲＲＫ２阻害薬としての新規のイミダゾ［４，５−ｃ］キノリンおよびイミダゾ［４，５−ｃ］［１，５］ナフチリジン誘導体
US9762007B2 (en)	2016-02-10	2017-09-12	Dish Network L.L.C.	Push on connector
US20180072718A1 (en)	2016-09-09	2018-03-15	Incyte Corporation	Pyrazolopyridine compounds and uses thereof
JP7076432B2 (ja)	2016-09-09	2022-05-27	インサイト・コーポレイション	Ｈｐｋ１調節薬としてのピラゾロピリジン誘導体及びがんの治療のためのその用法
WO2018049191A1 (fr)	2016-09-09	2018-03-15	Incyte Corporation	Dérivés de pyrazolopyridone en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
WO2018049152A1 (fr)	2016-09-09	2018-03-15	Incyte Corporation	Dérivés de pyrazolopyrimidine en tant que modulateurs de hpk1 et leurs utilisations pour le traitement du cancer
CA3037748A1 (fr) *	2016-09-30	2018-04-05	Asana Biosciences, Llc	Composes p2x3 et/ou p2x2/3 et methodes associees
CN106620315A (zh) *	2016-11-17	2017-05-10	郑州郑先医药科技有限公司	一种用于治疗风湿病的药物组合物
CN106667990A (zh) *	2016-11-17	2017-05-17	郑州郑先医药科技有限公司	一种治疗风湿病的药物
CN106580974A (zh) *	2016-12-06	2017-04-26	郑州郑先医药科技有限公司	一种治疗脊髓损伤的西药组合物及其应用
US20180153922A1 (en)	2016-12-06	2018-06-07	New York Society For The Ruptured And Crippled Maintaining The Hospital For Special Surgery	Inhibition of expansion and function of pathogenic age-associated b cells and use for the prevention and treatment of autoimmune disease
WO2018147612A1 (fr) *	2017-02-07	2018-08-16	주식회사 온코크로스	Composition destinée à inhiber la métastase cancéreuse et à traiter le cancer
WO2018152220A1 (fr)	2017-02-15	2018-08-23	Incyte Corporation	Composés de pyrazolopyridine et leurs utilisations
BR112019021992A2 (pt) *	2017-04-21	2020-06-09	Kyn Therapeutics	inibidores de ahr de indol e usos dos mesmos
WO2019051199A1 (fr)	2017-09-08	2019-03-14	Incyte Corporation	Composés de 6-cyano-indazole utilisés en tant que modulateurs de kinase 1 progénitrices hématopoïétiques (hpk1)
CN108178760B (zh) *	2017-12-27	2020-02-18	安徽医科大学	一种嘧啶并吡唑杂环化合物、制备方法、用途
WO2019164847A1 (fr)	2018-02-20	2019-08-29	Incyte Corporation	Composés d'indazole et leurs utilisations
US10745388B2 (en)	2018-02-20	2020-08-18	Incyte Corporation	Indazole compounds and uses thereof
SMT202200294T1 (it)	2018-02-20	2022-11-18	Incyte Corp	Derivati di n-(fenil)-2-(fenil)pirimidina-4-carbossammide e composti correlati come inibitori di hpk1 per trattare il cancro
WO2019162964A1 (fr) *	2018-02-23	2019-08-29	Indian Institute Of Science	Composition anti-tuberculeuse, et mises en œuvre de cette dernière en association
US10689386B2 (en)	2018-03-07	2020-06-23	Duquesne University Of The Holy Spirit	Pyrazolo[4,3-d]pyrimidines as antitumor agents
US11299473B2 (en)	2018-04-13	2022-04-12	Incyte Corporation	Benzimidazole and indole compounds and uses thereof
US10899755B2 (en)	2018-08-08	2021-01-26	Incyte Corporation	Benzothiazole compounds and uses thereof
TW202028207A (zh)	2018-09-25	2020-08-01	美商英塞特公司	吡唑并嘧啶化合物及其用途
CN109867800B (zh) *	2019-04-01	2021-04-09	江西理工大学	一种镉基金属-有机框架及其制备方法
MX2021014273A (es) *	2019-05-21	2022-01-06	Voronoi Inc	Derivado de heteroarilo que contiene n y composicion farmaceutica que lo comprende como principio activo para la prevencion o el tratamiento de cancer.
WO2020247756A1 (fr) *	2019-06-05	2020-12-10	Forcyte Biotechnologies, Inc.	Petites molécules pour relaxer les contractions des muscules lisses de l'utérus
WO2021007108A1 (fr) *	2019-07-05	2021-01-14	Icahn School Of Medicine At Mount Sinai	Méthode de prévention contre la perte de cheveux
WO2021026180A1 (fr)	2019-08-06	2021-02-11	Incyte Corporation	Formes solides d'un inhibiteur d'hpk 1
CN110876752B (zh) *	2019-11-18	2021-04-30	暨南大学	长链非编码rna nron功能基序在制备抑制骨吸收及防治骨质疏松药物中的应用
JP2023502531A (ja)	2019-11-26	2023-01-24	イケナオンコロジー，インコーポレイテッド	多形カルバゾール誘導体およびその使用
JP7483810B2 (ja)	2021-08-31	2024-05-15	日本たばこ産業株式会社	６－アミノピラゾロピリミジン化合物及びその医薬用途
WO2023076404A1 (fr)	2021-10-27	2023-05-04	Aria Pharmaceuticals, Inc.	Méthodes de traitement de lupus érythémateux disséminé
WO2024107658A2 (fr) *	2022-11-16	2024-05-23	Vyrnwy Therapeutics, Inc.	Inhibiteurs de tyk2

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4469868A (en) *	1982-05-24	1984-09-04	Warner-Lambert Company	Alkylimidazo[1,2-c]pyrazolo[3,4-e]pyrimidines
GB8306481D0 (en) *	1983-03-09	1983-04-13	Beecham Group Plc	Compounds
US5360720A (en)	1993-10-08	1994-11-01	Alcon Laboratories, Inc.	Method of preparing human conjunctival mast cells for mast cell stabilization assays
US5723608A (en) *	1996-12-31	1998-03-03	Neurogen Corporation	3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands
US6531475B1 (en) *	1998-11-12	2003-03-11	Neurocrine Biosciences, Inc.	CRF receptor antagonists and methods relating thereto
DE19942474A1 (de) *	1999-09-06	2001-03-15	Merck Patent Gmbh	Pyrazolo[4,3-d]pyrimidine
DE10113710A1 (de)	2001-03-16	2002-09-26	Joerg Rademann	Oxoammoniumsalze sowie deren Verwendung
GB0106661D0 (en) *	2001-03-16	2001-05-09	Pfizer Ltd	Pharmaceutically active compounds
DK1348707T3 (da) *	2002-03-28	2010-12-13	Ustav Ex Botan Av Cr V V I Inst Of Ex Botany Academy Of Sciences Of The Czech Republic Pro	Pyrazolo[4,3-d]pyrimidiner, fremgangsmåder til deres fremstilling samt deres terapeutiske anvendelse
US20030139427A1 (en) *	2002-08-23	2003-07-24	Osi Pharmaceuticals Inc.	Bicyclic pyrimidinyl derivatives and methods of use thereof
AU2003297160A1 (en)	2002-12-18	2004-07-22	Vertex Pharmaceuticals Incorporated	Benzisoxazole derivatives useful as inhibitors of protein kinases
MEP8409A (en) *	2004-06-02	2011-12-20		Fused heterocyclic compound
PT1881985E (pt)	2005-05-12	2011-02-01	Pfizer	Formas cristalinas anidras de n-[1-(2-etoxietil)-5-(n- -etil-n-metilamino)-7-(4-metilpiridin-2-il-amino)-1h- -pirazolo[4,3-d]pirimidino-3-carbonil]metanossulfonamida
WO2006126718A1 (fr)	2005-05-27	2006-11-30	Tanabe Seiyaku Co., Ltd.	Dérivé de pyrazolopyrimidine
JP2007055940A (ja)	2005-08-24	2007-03-08	Astellas Pharma Inc	ピラゾロピリミジン誘導体
NL2000291C2 (nl)	2005-11-10	2009-02-17	Pfizer Prod Inc	1-(1-(2-ethoxyethyl)-3-ethyl-7-(4-methylpyridin-2-ylamino)-1H- pyrazool(4,3-d)pyrimidine-5-yl)piperidine-4-carbonzuur en zouten daarvan.
CN101611035A (zh) *	2006-12-28	2009-12-23	大正制药株式会社	吡唑并嘧啶化合物
AU2009215191A1 (en)	2008-02-13	2009-08-20	Gilead Connecticut, Inc.	6-aryl-imidaz0[l, 2-a] pyrazine derivatives, method of making, and method of use thereof
MX2011006094A (es)	2008-12-08	2011-11-29	Gilead Connecticut Inc	Inhibidores de imidazopirazina syk.
WO2010118367A2 (fr)	2009-04-10	2010-10-14	Progenics Pharmaceuticals, Inc.	Pyrimidines antivirales
WO2010129053A2 (fr)	2009-05-05	2010-11-11	Dana Farber Cancer Institute	Inhibiteurs d'egfr et procédés de traitement de troubles
US9802937B2 (en)	2011-04-21	2017-10-31	Origenis Gmbh	Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitors
AR090650A1 (es)	2012-04-12	2014-11-26	Alcon Res Ltd	Tratamiento para respuestas inflamatorias inducidas por microbios en el ojo

2012
- 2012-04-23 US US13/506,510 patent/US9802937B2/en active Active
- 2012-04-23 WO PCT/EP2012/001737 patent/WO2012143144A1/fr active Application Filing
- 2012-04-23 SG SG2013077920A patent/SG194549A1/en unknown
- 2012-04-23 CN CN201280019429.4A patent/CN103492389B/zh active Active
- 2012-04-23 AP AP2013007253A patent/AP2013007253A0/xx unknown
- 2012-04-23 MX MX2013012294A patent/MX363696B/es unknown
- 2012-04-23 PH PH1/2013/502185A patent/PH12013502185A1/en unknown
- 2012-04-23 TW TW101114348A patent/TWI606049B/zh active
- 2012-04-23 JP JP2014505544A patent/JP6222776B2/ja active Active
- 2012-04-23 PE PE2013002376A patent/PE20140928A1/es active IP Right Grant
- 2012-04-23 EP EP12717198.1A patent/EP2699579B1/fr active Active
- 2012-04-23 AU AU2012244550A patent/AU2012244550C1/en active Active
- 2012-04-23 CA CA2831634A patent/CA2831634C/fr active Active
- 2012-04-23 EA EA201301184A patent/EA029040B1/ru unknown
- 2012-04-23 BR BR112013026521A patent/BR112013026521A2/pt not_active Application Discontinuation
- 2012-04-23 KR KR1020137030320A patent/KR101649611B1/ko active Active
2013
- 2013-10-14 TN TNP2013000419A patent/TN2013000419A1/fr unknown
- 2013-10-18 GT GT201300255A patent/GT201300255A/es unknown
- 2013-10-20 IL IL228968A patent/IL228968A/en active IP Right Grant
- 2013-10-21 CL CL2013003051A patent/CL2013003051A1/es unknown
- 2013-10-21 CO CO13249372A patent/CO6831982A2/es unknown
- 2013-10-21 ZA ZA2013/07839A patent/ZA201307839B/en unknown
- 2013-10-21 EC ECSP13012982 patent/ECSP13012982A/es unknown
- 2013-10-21 CU CU2013000143A patent/CU20130143A7/es unknown
- 2013-10-21 CR CR20130536A patent/CR20130536A/es unknown
- 2013-11-14 MA MA36430A patent/MA35124B1/fr unknown
2014
- 2014-06-16 HK HK14105693.3A patent/HK1192248A1/xx unknown

Also Published As

Publication number	Publication date
CA2831634A1 (fr)	2012-10-26
HK1192248A1 (en)	2014-09-05
MA35124B1 (fr)	2014-05-02
SG194549A1 (en)	2013-12-30
CN103492389A (zh)	2014-01-01
JP6222776B2 (ja)	2017-11-01
KR101649611B1 (ko)	2016-08-19
MX2013012294A (es)	2014-06-23
GT201300255A (es)	2015-03-16
EA201301184A1 (ru)	2014-08-29
CL2013003051A1 (es)	2014-07-11
TWI606049B (zh)	2017-11-21
CO6831982A2 (es)	2014-01-10
AU2012244550C1 (en)	2017-06-22
KR20140004771A (ko)	2014-01-13
EA029040B1 (ru)	2018-02-28
ECSP13012982A (es)	2014-09-30
CN103492389B (zh)	2016-09-14
AU2012244550A1 (en)	2013-10-31
AP2013007253A0 (en)	2013-11-30
IL228968A0 (en)	2013-12-31
US20120329780A1 (en)	2012-12-27
PE20140928A1 (es)	2014-08-24
ZA201307839B (en)	2015-02-25
PH12013502185A1 (en)	2014-01-13
IL228968A (en)	2017-11-30
AU2012244550B2 (en)	2017-04-06
CR20130536A (es)	2014-03-13
TW201245205A (en)	2012-11-16
EP2699579A1 (fr)	2014-02-26
US9802937B2 (en)	2017-10-31
JP2014511885A (ja)	2014-05-19
CA2831634C (fr)	2019-11-12
CU20130143A7 (es)	2014-02-28
EP2699579B1 (fr)	2015-10-07
WO2012143144A1 (fr)	2012-10-26
MX363696B (es)	2019-03-28
BR112013026521A2 (pt)	2016-12-27

Publication	Publication Date	Title
TN2013000419A1 (en)	2015-03-30	Pyrazolo [4, 3-d] pyrimidines useful as kinase inhibitors
TN2013000422A1 (en)	2015-03-30	Heterocyclic compounds as kinase inhibitors
PH12016502060A1 (en)	2017-09-18	Processes for preparing jak inhibitors and related intermediate compounds
MX2013012983A (es)	2013-12-06	Composiciones y metodos para la produccion de compuestos de pirimidina con actividad inhibidora de tirosina cinasa de bruton.
SI3418281T1 (sl)	2021-02-26	Pirazolo(1,5-A)pirimidini, uporabni kot zaviralci kinaze ATR za zdravljenje rakavih obolenj
MX2011012353A (es)	2011-12-14	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
WO2015006754A3 (fr)	2015-03-12	Composés hétérocycliques et leurs utilisations
SG179120A1 (en)	2012-05-30	Novel compounds
MY161416A (en)	2017-04-14	3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4yl)-1h-pyrazol-1-yl]octane-or heptane-nitrile as jak inhibitors
WO2014093230A3 (fr)	2014-08-28	Compositions et procédés de fabrication de composés pyrimidine et pyridine ayant une activité inhibitrice de btk
AR086196A1 (es)	2013-11-27	Derivados de pirazolo[3,4-c]quinolina, inhibidores de quinasa
TH115252A (th)	2012-07-31	กรรมวิธีสำหรับการเตรียมตัวยับยั้ง jak และสารประกอบตัวกลางที่เกี่ยวข้อง